Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 161,672
  • Shares Outstanding, K 54,435
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,800 K
  • 60-Month Beta 2.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.48
Trade ONCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.58 +12.79%
on 05/17/21
3.21 -9.35%
on 06/01/21
+0.27 (+10.23%)
since 05/14/21
3-Month
2.58 +12.79%
on 05/17/21
4.83 -39.75%
on 04/08/21
-0.08 (-2.68%)
since 03/12/21
52-Week
1.52 +91.45%
on 09/04/20
4.83 -39.75%
on 04/08/21
+0.89 (+44.06%)
since 06/12/20

Most Recent Stories

More News
Thinking about buying stock in Oncternal Therapeutics, Polarityte, Adaptimmune Therapeutics, Oncolytics Biotech, or Precipio?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCT, PTE, ADAP, ONCY, and PRPO.

ADAP : 4.49 (+0.67%)
ONCT : 5.49 (+1.29%)
ONCY : 2.91 (-2.02%)
PTE : 1.1400 (+2.70%)
PRPO : 3.99 (+3.64%)
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment

PALM BEACH,  Fla., /PRNewswire/ -- Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of...

TRIL : 9.77 (+0.31%)
TRIL.TO : 11.83 (+0.17%)
ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)
ATNX : 5.13 (+2.40%)
SEEL : 3.39 (+0.89%)
MRKR : 3.56 (+6.27%)
Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination...

ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare...

ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

COMTEX_386258164/2669/2021-05-10T07:00:54

ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results

ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)
Oncolytics Biotech® Announces Annual General Meeting

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), (the "") today announced that its upcoming 2021 Annual General Meeting (the "") will be held virtually at (ET) on . In light...

ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical...

ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)
Thinking about buying stock in Dolphin Entertainment, Golden Ocean Group, Energous Corp, Oncolytics Biotech, or Oncternal Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DLPN, GOGL, WATT, ONCY, and ONCT.

DLPN : 9.33 (-3.72%)
GOGL : 10.74 (-3.16%)
ONCT : 5.49 (+1.29%)
ONCY : 2.91 (-2.02%)
WATT : 2.94 (-2.00%)
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients...

ONCY : 2.91 (-2.02%)
ONC.TO : 3.54 (-1.39%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 3.07
2nd Resistance Point 3.03
1st Resistance Point 2.97
Last Price 2.91
1st Support Level 2.87
2nd Support Level 2.84
3rd Support Level 2.78

See More

52-Week High 4.83
Fibonacci 61.8% 3.57
Fibonacci 50% 3.17
Last Price 2.91
Fibonacci 38.2% 2.78
52-Week Low 1.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar